viewAmryt Pharma PLC

Amryt Pharma inks distribution deal covering central and eastern Europe with Swiss partner

Swixx BioPharma, which also has the exclusive contract for Amryt’s Myalepta, will start deliveries of Lojuxta later this month

Amryt Pharma PLC -

Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT) said it has signed a distribution deal for Lojuxta covering 17 countries in central and eastern Europe (CEE).

Swixx BioPharma, which also has the exclusive contract for Amryt’s Myalepta, will start deliveries later this month.

Lojuxta, also known as lomitapide, has been developed to treat adults with a rare cholesterol disorder.

“Lomitapide is an important contributor to Amryt’s commercial performance and growth and today’s announcement demonstrates the progress we are making in expanding lomitapide’s reach in existing and new territories,” said chief executive Joe Wiley in a statement

“This agreement will help bring lomitapide to even more patients in need. Also, we are excited to grow and consolidate our existing partnership with Swixx who currently distribute metreleptin exclusively across the CEE territories.”

Quick facts: Amryt Pharma PLC

Price: 196 GBX

Market: AIM
Market Cap: £319.09 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...


Amryt Pharma reports record Q3 2020 results, delivering 19% year on year growth

Amryt Pharma's LON:AMYT) Joe Wiley talks to Proactive New York's Christine Corrado about their latest record Q3 2020 Results. The results have lead to the full year guidance being raised which Wiley puts down to two launched commercial assents, metreleptin and lomitapide. Wiley talks...

1 month ago

2 min read